AbbVie said on Friday that the U.S. Food and Drug Administration approved its drug for complicated intra-abdominal infections ...

NORTH CHICAGO, Ill. - The U.S. Food and Drug Administration (FDA) has approved EMBLAVEO™ (aztreonam and avibactam) for the ...

The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...

根据2024年ASCO上公布的PALOMA 3期临床试验，皮下注射版本的埃万妥与拉泽替尼组合，有效性安全性均优于当下的静脉注射版埃万妥+拉泽替尼。但在24年12月，由于生产上的问题，埃万妥皮下注射版本收到FDA的CRL，目前不确定何时能上市。

The FDA has approved Journavx, a new non-opioid painkiller designed to treat moderate to severe acute pain. Unlike opioids, ...

Onapgo is a subcutaneous apomorphine infusion device for the treatment of motor fluctuations in patients with advanced disease ...

If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...

The first clinical trials using organs from genetically modified pigs offer hope to patients with kidney failure, who face a ...

The FDA will allow two biotechnology companies to run clinical trials: United Therapeutics and eGenesis. United Therapeutics ...

The U.S. Food and Drug Administration has approved Supernus Pharmaceuticals' drug-device combination to treat ...

The FDA has approved the intravenous antibiotic Emblaveo for adults with complicated intra-abdominal infections who have limited treatment options.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...